Overview

Semaglutide for Post-Smoking Cessation Weight Management

Status:
Recruiting
Trial end date:
2026-08-01
Target enrollment:
Participant gender:
Summary
This trial will examine the effect of semaglutide 2.4mg on changes in body weight, body composition, and peripheral and central mechanisms that control appetite, satiety, and food intake in the context of smoking cessation.
Phase:
Phase 2
Details
Lead Sponsor:
The University of Texas Health Science Center, Houston
Treatments:
Nicotine
Semaglutide